Abstract
Chemotherapeutic agents targeting the human epidermal receptor (HER) family are being used with increasing frequency for a variety of solid tumors. Cutaneous side effects are commonly reported with HER inhibitors, especially those agents that inhibit epidermal growth factor receptor (EGFR) or HER1. However, inhibitors of HER2 are not associated with specific skin toxicity. We present a case of tufted hair folliculitis, an inflammatory scalp condition causing scaling and pruritus, in a woman being treated with trastuzumab, a selective HER2 inhibitor. This finding has not previously been reported as a side effect of trastuzumab therapy.
Similar content being viewed by others
References
Annessi G (1998) Tufted folliculitis of the scalp: a distinctive clinicohistological variant of folliculitis decalvans. Br J Dermatol 138:799–805
Ena P, Fadda GM, Ena L, Farris A, Santeufemia DA (2008) Tufted hair folliculitis in a woman treated with lapatinib for breast cancer. Clin Exp Dermatol 33:776–794. doi:10.111/j.1365-2230.2008.02882.x
Myskowski PL, Halpern AC (2009) Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care 3:294–299. doi:10.1097/SPC.0b013e328332d397
Laux I, Jain A, Singh S, Agus DB (2006) Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 94:85–92. doi:10.1038/sj.bjc.6602875
De Potter IY, Poumay Y, Squillace KA, Pittelkow MR (2001) Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res 271:315–328. doi:10.1006/excr.2001.5390
Conflict of interest statement
The author(s) has/have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosman, I.S., Anadkat, M.J. Tufted hair folliculitis in a woman treated with trastuzumab. Targ Oncol 5, 295–296 (2010). https://doi.org/10.1007/s11523-010-0162-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-010-0162-5